As the use of GLP-1 weight-loss drugs rises among Americans, major retailers are adapting to a changing landscape where employers are reducing coverage for these medications. This trend is pushing more consumers towards direct-to-consumer (DTC) prescription programs, providing retailers with an opportunity to capture a larger market share.
Retailers are not merely selling prescriptions; they are leveraging these medications to build lasting customer relationships that extend to other products in their stores. Eric Bormel, managing director at Solomon Partners, emphasizes that retailers view the ecosystem surrounding GLP-1 medications as more valuable than the drugs themselves, which are facing price pressures.
Jackie Swanson from Gartner Consulting notes that the prescription refill model creates a unique loyalty dynamic, as customers are likely to purchase additional items while visiting the pharmacy.
Walmart, which holds 4.8% of the pharmacy market, is aggressively expanding its services to include weight-management support alongside GLP-1 prescriptions, aiming to position itself as a comprehensive healthcare destination. Meanwhile, Amazon is also entering the fray with its GLP-1 management program through One Medical, offering competitive pricing and same-day delivery.
However, this shift poses challenges for independent pharmacies, which may lose customers to larger chains. The overall trend indicates that as employers withdraw from covering GLP-1 drugs, retailers are poised to become the primary providers of obesity care, creating a new battleground in the retail pharmacy sector